Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Other Operating Expenses (2016 - 2025)

Organogenesis Holdings has reported Other Operating Expenses over the past 6 years, most recently at $321.4 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $321.4 million for Q4 2025, up 209.88% from a year ago — trailing twelve months through Dec 2025 was $300.6 million (up 64.72% YoY), and the annual figure for FY2025 was $148.7 million, up 7.33%.
  • Other Operating Expenses for Q4 2025 was $321.4 million at Organogenesis Holdings, up from -$56.7 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for ORGO hit a ceiling of $321.4 million in Q4 2025 and a floor of -$207.7 million in Q4 2023.
  • Median Other Operating Expenses over the past 3 years was $28.1 million (2024), compared with a mean of $34.4 million.
  • Peak annual rise in Other Operating Expenses hit 209.88% in 2025, while the deepest fall reached 311.65% in 2025.
  • Organogenesis Holdings' Other Operating Expenses stood at -$207.7 million in 2023, then surged by 149.95% to $103.7 million in 2024, then soared by 209.88% to $321.4 million in 2025.
  • The last three reported values for Other Operating Expenses were $321.4 million (Q4 2025), -$56.7 million (Q3 2025), and $29.4 million (Q2 2025) per Business Quant data.